STAT+: Pharmalittle: We’re reading about AstraZeneca cost-cutting, Sun Pharma facility problems, and more
AstraZeneca has launched a three-year cost-cutting program that aims to slice off $1.5 billion a year, with the savings reinvested in R&D
Pharmalittle: AstraZeneca is rolling out a three-year cost-cutting plan, aiming to trim $1.5 billion annually from its operations. The savings will be reinvested back into research and development, according to Pharmaphorum. The company has estimated a one-time charge of around $2 billion, with the program set to conclude by the end of 2029.
Sun Pharmaceutical, on the other hand, is dealing with quality management issues at its Assam facility, leading to its shutdown by Indian regulators. The drugs control organization and Drugs Controller Assam cited lapses in the system, following a voluntary recall of 11 eye-care brands by Sun Pharma in July. The facility was anticipated to become a significant manufacturing hub for sterile products, a sector considered a major global growth driver.
Written by urgent.news from STAT News's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
